RIMACTANE Drug Patent Profile
✉ Email this page to a colleague
When do Rimactane patents expire, and when can generic versions of Rimactane launch?
Rimactane is a drug marketed by Oxford Pharms and is included in one NDA.
The generic ingredient in RIMACTANE is rifampin. There are nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rimactane
A generic version of RIMACTANE was approved as rifampin by EPIC PHARMA LLC on May 28th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RIMACTANE?
- What are the global sales for RIMACTANE?
- What is Average Wholesale Price for RIMACTANE?
Summary for RIMACTANE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Clinical Trials: | 7 |
| Patent Applications: | 6,837 |
| DailyMed Link: | RIMACTANE at DailyMed |
Recent Clinical Trials for RIMACTANE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Cape Town | Phase 3 |
| Epizyme, Inc. | Phase 1 |
| University of Cape Town | Phase 1 |
US Patents and Regulatory Information for RIMACTANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxford Pharms | RIMACTANE | rifampin | CAPSULE;ORAL | 050429-001 | Approved Prior to Jan 1, 1982 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
